Literature DB >> 11471659

A nuclear complex containing PPARalpha/RXRalpha is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function.

H Kanda1, R Nohara, K Hasegawa, C Kishimoto, S Sasayama.   

Abstract

The expression of genes encoding fatty acid utilization enzymes is coordinately downregulated during the development of cardiac hypertrophy and failure. However, molecular mechanisms that mediate this downregulation are unknown. Peroxisome proliferator-activated receptor (PPAR) response elements (PPREs) have been identified in promoters of many genes involved in fatty acid utilization, where they function as positive regulatory elements. PPARs bind to PPREs as heterodimers with retinoid X receptors (RXRs). Primary cardiac myocytes from neonatal rats were transfected with a reporter construct driven by the C promoter of rat acyl-coenzyme A synthetase (ACS) gene. Stimulation with phenylephrine, a potent inducer of hypertrophy, markedly downregulated the activity of this promoter. By use of electrophoretic mobility-shift assays (EMSAs) using PPRE in the rat ACS promoter as a probe, we found a sequence-specific protein-DNA complex in the nuclear extract from adult rat left ventricular (LV) myocardium. Supershift experiments revealed that this complex was immunoreactive for PPARalpha and RXRalpha. We compared the activity of this complex in LV nuclear extracts from Dahl salt-sensitive rats (DSs) with hypertension and control age-matched Dahl salt-resistant rats (DRs). Even at the stage of concentric LV hypertrophy with normal systolic function, the activity of the band was markedly diminished in DSs compared with DRs. However, immunoblot analyses showed no difference in LV expression levels of PPARalpha or RXRalpha between DSs and DRs. These findings indicate that a nuclear complex of PPARalpha/RXRalpha is present in adult rat LV and is markedly downregulated in the hypertrophied LV from DS rats, which may account for the loss of transcriptional activation. The downregulation of this complex precedes LV systolic dysfunction and is mediated at the posttranslational levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11471659     DOI: 10.1007/s003800070022

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  13 in total

Review 1.  Mitochondrial SIRT3 and heart disease.

Authors:  Vinodkumar B Pillai; Nagalingam R Sundaresan; Valluvan Jeevanandam; Mahesh P Gupta
Journal:  Cardiovasc Res       Date:  2010-08-04       Impact factor: 10.787

Review 2.  Mitochondrial energy metabolism in heart failure: a question of balance.

Authors:  Janice M Huss; Daniel P Kelly
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  Maintaining ancient organelles: mitochondrial biogenesis and maturation.

Authors:  Rick B Vega; Julie L Horton; Daniel P Kelly
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

Review 4.  Cardiac nuclear receptors: architects of mitochondrial structure and function.

Authors:  Rick B Vega; Daniel P Kelly
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

5.  Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach.

Authors:  Ling Lai; Teresa C Leone; Mark P Keller; Ola J Martin; Aimee T Broman; Jessica Nigro; Kapil Kapoor; Timothy R Koves; Robert Stevens; Olga R Ilkayeva; Rick B Vega; Alan D Attie; Deborah M Muoio; Daniel P Kelly
Journal:  Circ Heart Fail       Date:  2014-09-18       Impact factor: 8.790

Review 6.  Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy.

Authors:  Naveen Sharma; Isidore C Okere; Monika K Duda; David J Chess; Karen M O'Shea; William C Stanley
Journal:  Cardiovasc Res       Date:  2006-11-11       Impact factor: 10.787

7.  Cardiomyocyte peroxisome proliferator-activated receptor α is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling.

Authors:  Xia Wang; Xin-Xin Zhu; Shi-Yu Jiao; Dan Qi; Bao-Qi Yu; Guo-Min Xie; Ye Liu; Yan-Ting Song; Qing Xu; Qing-Bo Xu; Frank J Gonzalez; Jie Du; Xiao-Min Wang; Ai-Juan Qu
Journal:  Acta Pharmacol Sin       Date:  2021-08-10       Impact factor: 7.169

8.  Myocardial metabolic regulation through peroxisome proliferator-activated receptor alpha after myocardial infarction.

Authors:  Katsuhiko Masamura; Nobuyoshi Tanaka; Masahiro Yoshida; Masayuki Kato; Yasuyuki Kawai; Koji Oida; Isamu Miyamori
Journal:  Exp Clin Cardiol       Date:  2003

9.  Inactivation of peroxisome proliferator-activated receptor isoforms alpha, beta/delta, and gamma mediate distinct facets of hypertrophic transformation of adult cardiac myocytes.

Authors:  Corinne Pellieux; Christophe Montessuit; Irène Papageorgiou; René Lerch
Journal:  Pflugers Arch       Date:  2007-07-21       Impact factor: 3.657

10.  Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.

Authors:  Vinodkumar B Pillai; Sadhana Samant; Nagalingam R Sundaresan; Hariharasundaram Raghuraman; Gene Kim; Michael Y Bonner; Jack L Arbiser; Douglas I Walker; Dean P Jones; David Gius; Mahesh P Gupta
Journal:  Nat Commun       Date:  2015-04-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.